Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks bleeding risks and Pill-Taking habits in heart patients

NCT ID NCT07458191

Knowledge-focused Sponsor: Bosnalijek D.D Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study watches 800 adults with nonvalvular atrial fibrillation (a type of irregular heartbeat) who are starting the blood thinner apixaban for the first time. Researchers will track how often serious or minor bleeding occurs and how well patients stick to their medication schedule over six months. The goal is to better understand the real-world safety and adherence to this common treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 800 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Eligible patients from participating centers from Bosnia and Herzegovina who are treated on an outpatient basis or in a hospital setting.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients over 18 years of age. * Hemodynamically stable patients. * Patients with non-valvular atrial fibrillation. * Patients in whom the investigator, based on clinical assessment makes a decision to introduce apixaban therapy. * Patients who are on apixaban therapy for the first time Exclusion Criteria: * Positive history of angioneurotic edema. * Active, clinically significant bleeding. * Congenital or acquired bleeding disorder. * The presence of a malignant tumor. * Current or recent presence of gastrointestinal ulcer. * The presence of established or suspected esophageal varices. * Positive history of arteriovenous malformations, vascular aneurysms or intraspinal and intracerebral vascular anomalies. * Patients with artificial heart valves. * Liver cirrhosis and active liver disease associated with coagulopathy and clinically significant risk of bleeding. * Dialysis patients (GFR \<15 ml/min). * Simultaneous use of other anticoagulants. * Pregnancy and breastfeeding. * Patients who previously used apixaban in therapy. Withdrawal Criteria: * Deterioration of the clinical picture of the underlying disease that requires discontinuation of investigational therapy. * Development of serious adverse events that require discontinuation of therapy. * Occurrence of pregnancy. * Development of another disease that affects the course of research.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nonvalvular atrial fibrillation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nonvalvular atrial fibrillation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clinic for diseases of the heart, blood vessels and rheumatism

    RECRUITING

    Sarajevo, 71000, Bosnia and Herzegovina

More trials for these conditions

Other studies related to the condition(s) this trial covers.